MA-BENU-NETWORKS
13.8.2019 13:37:10 CEST | Business Wire | Press release
Benu Networks , the leading software and solutions provider simplifying the industry’s most complex edge networks, announced the launch of its new virtual broadband network gateway (vBNG ). This new network function builds upon Benu Networks’ Software-Defined Edge (SD-Edge) Platform, which features a set of rich, virtualized functionalities that enable service providers to instantly cloudify their network, rapidly create and deliver new services, and easily scale network performance.
Modern consumer expectation and demand, particularly from the lens of a managed service provider, is constantly shifting. Buying behavior and criteria have drastically changed - gone are the days when triple play deals created great value to consumers and helped drive ARPU growth for service providers. Nowadays, residential subscribers are moving to single play broadband access, which adds pressure for managed service providers to create customized, cutting-edge offerings that continue to impress consumers. However, this level of agility has proved difficult to achieve for most MSPs, who still depend on hardware to manage subscriber sessions, authentication, and more. Plus, the need to reduce operational and capital expenses in the midst of margin erosion adds an additional layer of complexity for MSPs to manage.
“Our network has relied on Benu Networks’ software for 4 years, on dedicated appliances. We’re thrilled to see the addition of a vBNG to their platform,” said Khetan Gajjar, CTO of VAST Networks. “One of the key challenges we face, particularly as Africa’s leading Wi-Fi provider of services, is our ability to be agile and dynamic with the services we offer and scaling these efficiently while retaining our standard of performance. We currently do this with the SD-Edge Platform to millions of users. Now, with the Benu vBNG, we won’t have to think too hard about the scaling required to tailor services to each customer and building out new offerings and scaling to tens and hundreds of millions of users. A vBNG also allows us to deliver network scale much closer to the edge and allows us to expand into markets much more cost-effectively.”
The vBNG, running on the Benu SD-Edge Platform, helps service providers achieve this vision by streamlining packet processing as well as separating the control plane and data plane for dynamic scaling, added agility, optimal network performance, and cost reduction. The flexible, open architecture supports 3rd party service stitching on top of the breadth of functionality native to the vBNG. Service providers can now consolidate functions such as TDF/DPI, CGNAT, SG, and BNG, into a single virtualized platform for ultra-low latency and high performance. With the Benu Networks vBNG, service providers can go beyond just providing a ‘dumb pipe’ broadband connection and instead rapidly provision value-added services that reduce churn and increase ARPU.
“Releasing our vBNG as a part of the Benu SD-Edge Platform furthers our mission to simplify edge applications, “ said Mads Lillelund, CEO of Benu Networks. “We’re looking to drastically simplify network transformation and make it easy for service providers to be more agile and innovative without locking them into one vendor. With our vBNG, we’ve taken a massive step toward achieving this goal.”
The vBNG virtualizes integral network functionality, empowering service providers to seamlessly transition to a cloud-based 5G ready network. Benu Networks’ technology simplifies the complexity of network optimization, helping service providers rapidly scale their offerings, manage their network, and ensure the service experience. By disaggregating legacy network structures and eliminating hardware dependencies, service providers are free to move towards a modern network, reduce costs, and improve customer experience.
To schedule a demo, visit https://benunetworks.com/contact-us/ .
About Benu Networks:
Benu Networks is a leading software and solutions provider, simplifying the industry’s most complex edge networks. With a comprehensive set of products and innovative solutions coupled with over a decade in the industry, Benu Networks delivers solutions to instantly transform legacy access networks, elastically manage services, and carve the path to 5G. For more information, please visit the Benu Networks’ website: www.benunetworks.com . Follow us on Twitter @benunets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190813005390/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
